Pryor Benchmark Technology and Baitu Shengke reached a strategic cooperation to jointly build a biocalculation ecology, enabling multi-group research on tumors

This cooperation will combine the strengths of both sides, empower China's top clinical oncologists, and provide ideas for innovative drug research and development.
The two sides plan to develop advanced technology, long-term investment, continuous research, accumulate samples and large amounts of multi-group data, and enhance the re-use of data to help tumor multi-group research in the sub-sectors of gynaecological tumors, pancreatic cancer and prostate cancer.
around this collaboration, Pryor Benchmark will be based on the self-developed tumor multi-group artificial intelligence big data mining platform AIBERT? (AI-driven Big Data Analytics for Effective Response of Cancer Therapy) multi-dimensional, integrated analysis of genomics, functional, and pharmaceutical genomic data, using deep learning algorithms to support precision medicine and innovative drug transformation development.
recent years, Prysmal has partnered with a number of top pharmaceutical companies to fully reflect the company's "data-driven research and development" concept and demonstrate the value AIBERT can bring to pharmaceutical partners.
Hundred Tusheng will provide world-leading cutting-edge histology services to clinical oncologists through its own research and development of BioMap HOPE ,a multi-group intelligence platform, which is based on a high-performance bio-computing engine based on independent research and development, greatly improving the mining efficiency of large amounts of multi-axis heterogeneous biological data, through independent research and development and ecology Cooperation, integration of a variety of world-leading advanced histology technology, to provide users with "bottom-level independent", "intelligent analysis", "multi-group joint" multi-group services, so that clinical experts can efficiently obtain information insight in the single-cell scale and spatial transcription group, observation group and other multi-dimensional capabilities, greatly accelerate the clinical process of cutting-edge histology technology empowerment.
In addition to providing a capacity platform, Baitusheng Will set up a special fund in its newly launched RMB 1 billion multi-group research excellence grant program to provide financial support and free technical services for clinical projects of cooperation between the two sides, and to further increase investment in research projects, expand the sample and data dimensions of projects, and promote the transformation of results.
It is worth mentioning that the strategic cooperation reached between the two sides is an important step in the multi-group data mining cooperation since the third quarter of 2020, when Pryor Benchmark obtained the predecessor of Baitusheng, Baidu Venture Capital Bio-Investment Team's A-plus round of investment.
, Pryor Benchmark has established long-term cooperation with dozens of large-scale, research and development pharmaceutical companies at home and abroad, based on the company's independent development of histological data mining system AIBERT, to provide decision-making support for new drug research and development.
on this basis, Pry benchmark for pharmaceutical companies to provide from exploratory research, central laboratory services, accompanying diagnostic development, to "diagnosis / treatment synergy" and other full-process, one-stop service, efficient for cooperative pharmaceutical companies.
company's technical advantages, but also extended to the advantages of clinical precision testing products, in the Chinese market launched a number of products, to help clinical precision medicine practice, has covered hundreds of hospitals, Huaxi Hospital and other top hospitals in hospital sales.
bioMap BioMap is the first bio-computing-driven life sciences platform company in China, founded by Baidu founder Robin Li, and is committed to accelerating the development of new drugs and diagnostic products through long-term, large-scale investment, through the fusion and innovation of advanced AI technology and cutting-edge biotechnology, to create a new multi-group detection and analysis, high-volume experimental simulation, intelligent molecular discovery engine, and accelerate the development of new drugs and diagnostic products.
Baitusheng is committed to building an international leading level of multi-group ecology, through independent research and development and global investment, a variety of cutting-edge technologies and professional teams at home and abroad, jointly promote multi-level, multi-dimensional, continuous clinical large-queue analysis, to help cancer, self-exemption, aging-related diseases metabolic law mining, new biomarkers and target mining, accelerate the creation of more innovative drugs and diagnostic products.
At present, Baitu Health Has invested/cooperated with more than 50 global early technology companies and research teams, and will launch a 1 billion yuan investment in the "Multi-Group Research Excellence Program", enabling universities and clinical research units, cutting-edge groups, innovative pharmaceutical enterprises and other partners, using the technical support of the multi-group intelligent platform of 100 Tu, to carry out joint research on innovative, clinically valuable biomedical issues, and accelerate the transformation of results. "Life sciences has entered an era of multi-group student computing as the core driving force, and we look forward to building a broad alliance of cooperation with our industry peers to accelerate the development of innovative precision medicine products based on AI-cutting biotechnology two-wheel drive," said Liu Wei, CEO of
Baitusheng.
Pryco is an industry-leading oncology translational medicine company that has developed and built a number of excellent precision medicine products and services with multi-group technology as the core platform in the direction of multiple disease segments, and is pleased to be able to work with them again, through in-depth cooperation, to fully integrate the technological advantages of both sides, to make more ground-breaking applications in the field of disease segmentation, bringing new awareness and next-generation precision medicine products to disease diagnosis and treatment.
Precision Scientific is a "data-driven" oncology translational medicine company.
company has unique and leading-edge technologies in multi-group technology, bio-information, biostatity/machine learning, including genomics.
provides translational medical services based on histological data for pharmaceutical companies, provides decision support for new drug research and development, has the central laboratory testing capabilities to serve new drug research and development, and jointly promotes the development of accompanying diagnostic products with pharmaceutical companies;
has a high-level team with both technical and management capabilities, with core members from top research institutions, multinational pharmaceutical companies and top investment banks at home and abroad, including MD Anderson Cancer Center, Peking University, Chinese Academy of Sciences, Labcorp, Abbott, Roche and others.
company in Beijing, Suzhou, two places with international standards of the central laboratory.
2000 square meters, Beijing Laboratory has a mature high-volume sequencing, molecular biology and pathology platform, can provide a comprehensive NGS, PCR, immunogroupization and other testing services.
Suzhou Center Laboratory covers an area of 1000 square meters and is a leading multi-group center laboratory in China, including NGS, single-cell sequencing, gene expression spectrum analysis (Nanostring), protein spectrum, etc.
, founder/CEO of TheRaed Benchmark, said: "Transformational medicine, driven by histological data mining, will play an increasingly important role in the development of new drugs.
the past decade, the global market for new drug research and development is under pressure to be less efficient, and Chinese new drug research and development companies are increasingly feeling the intensity of homogenization competition.
how to help pharmaceutical companies partners, improve the efficiency of research and development of new drugs, the formation of differentiated advantages, has always been the focus of pry benchmark thinking.
In order to achieve this goal, Pryor Benchmark relies on its outstanding capabilities in multi-grouping, data mining and bio-informationology to build a one-stop empowerment service that covers key research and development decision support, multi-group center laboratories, and accompanying diagnostic development.
company independently developed a large number of multi-group data mining system AIBERT, in the development of key decisions to help pharmaceutical companies (targets, biomarkers, indications, etc.), has been widely recognized by the industry.
, Prysmal Benchmark Technology has formed in-depth cooperation with a number of leading research and development pharmaceutical companies to help partner pharmaceutical companies improve the success rate of research and development and accelerate the approval of new drugs.
BioMap relies on Baidu's ai accumulation to have a unique advantage in biometrics to focus on research and transformational applications of artificial intelligence and bio-computing technology in the field of disease segmentation, which is highly in line with the goals of Priscing.
Pury Benchmark looks forward to in-depth cooperation between the two sides, combined with Priscical's experience in oncology data mining, as well as the advantages of 100 tusheng in biometrics, to achieve complementary advantages, integration of more resources, for transformational medicine and innovative drug research and development to provide new momentum.
"Arterial Network Source: Arterial Network Copyright Notice: All text, images and audio and video materials on this website that indicate "Source: Mets Medicine" or "Source: MedSci Original" are owned by Metz Medical and may not be reproduced by any media, website or individual without authorization, and shall be reproduced with the words "Source: Mets Medicine".
all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
at the same time reproduced content does not represent the position of this site.
leave a message here